SciELO - Scientific Electronic Library Online

 
vol.22 número6Criterios de Sgarbossa: ¿es momento de actualizarlos?Denervación renal percutánea mediante el uso de catéter con balón en pacientes con hipertensión arterial resistente índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Colombiana de Cardiología

versión impresa ISSN 0120-5633

Resumen

ARISTIZABAL, Julián M. et al. Those "other" bradycardias. Rev. Colomb. Cardiol. [online]. 2015, vol.22, n.6, pp.298-304. ISSN 0120-5633.  https://doi.org/10.1016/j.rccar.2015.07.006.

Bradycardia is a common finding in the context of hospitalized patients. Sometimes it is incidentally detected and its clinical implications are minimized. But sometimes it is associated with the presence of symptoms or hemodynamic compromise in patients who warrant further intervention. The etiology of the bradycardia is not always easy to determine and it is not surprising that many studies are initiated in order to clarify the reason for the situation. Clinicians are familiar with the pharmacological and adverse effects of various drugs we use every day. Despite this, there are many drugs with potential to develop bradycardia in response to a less known pharmacological properties or effects related to rare but certainly significant effects. The aim of this review is to explain the pharmacological properties and clinical impact of some substances that have been associated with bradycardia, beyond which we all know, in order to target interventions to be performed in patients with pharmacological and reversible causes of bradycardia.

Palabras clave : Arrhythmias; Pharmacology; Sinoatrial node.

        · resumen en Español     · texto en Español     · Español ( pdf )